The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial
Open accessAbstract
BACKGROUND: High rates of patient attrition from care between HIV testing and antiretroviral therapy (ART) initiation have been documented in sub-Saharan Africa, contributing to persistently low CD4 cell counts at treatment initiation. One reason for this is that starting ART in many countries is a lengthy and burdensome process, imposing long waits and multiple clinic visits on patients. We estimated the effect on uptake of ART and viral suppression of an accelerated initiation algorithm that allowed treatment-eligible patients to be dispensed their first supply of antiretroviral medications on the day of their first HIV-related clinic visit. METHODS AND FINDINGS: RapIT (Rapid Initiation of Treatment) was an unblinded randomized controlled trial of single-visit ART initiation in two public sector clinics in South Africa, a primary health clinic (PHC) and a hospital-based HIV clinic. Adult (≥18 y old), non-pregnant patients receiving a positive HIV test or first treatment-eligible CD4 count were randomized to standard or rapid initiation. Patients in the rapid-initiation arm of the study ("rapid arm") received a point-of-care (POC) CD4 count if needed; those who were ART-eligible received a POC tuberculosis (TB) test if symptomatic, POC blood tests, physical exam, education, counseling, and antiretroviral (ARV) dispensing. Patients in the standard-initiation arm of the study ("standard arm") followed standard clinic procedures (three to five additional clinic visits over 2-4 wk prior to ARV dispensing). Follow up was by record review only. The primary outcome was viral suppression, defined as initiated, retained in care, and suppressed (≤400 copies/ml) within 10 mo of study enrollment. Secondary outcomes included initiation of ART ≤90 d of study enrollment, retention in care, time to ART initiation, patient-level predictors of primary outcomes, prevalence of TB symptoms, and the feasibility and acceptability of the intervention. A survival analysis was conducted comparing attrition from care after ART initiation between the groups among those who initiated within 90 d. Three hundred and seventy-seven patients were enrolled in the study between May 8, 2013 and August 29, 2014 (median CD4 count 210 cells/mm3). In the rapid arm, 119/187 patients (64%) initiated treatment and were virally suppressed at 10 mo, compared to 96/190 (51%) in the standard arm (relative risk [RR] 1.26 [1.05-1.50]). In the rapid arm 182/187 (97%) initiated ART ≤90 d, compared to 136/190 (72%) in the standard arm (RR 1.36, 95% confidence interval [CI], 1.24-1.49). Among 318 patients who did initiate ART within 90 d, the hazard of attrition within the first 10 mo did not differ between the treatment arms (hazard ratio [HR] 1.06; 95% CI 0.61-1.84). The study was limited by the small number of sites and small sample size, and the generalizability of the results to other settings and to non-research conditions is uncertain. CONCLUSIONS: Offering single-visit ART initiation to adult patients in South Africa increased uptake of ART by 36% and viral suppression by 26%. This intervention should be considered for adoption in the public sector in Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT01710397, and South African National Clinical Trials Register DOH-27-0213-4177.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Govindasamy, D., Ford, N., & Kranzer, K. (2012) · AIDS · doi:10.1097/qad.0b013e3283578b9b · Cited by 435
Jani, I. V., Sitoe, N. E., Alfai, E. R., Chongo, P. L., Quevedo, J. I., Rocha, B. M., Lehe, J. D., & Peter, T. F. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61052-0 · Cited by 264
Mfinanga, S., Chanda, D., Kivuyo, S. L., Guinness, L., Bottomley, C., Simms, V., Chijoka, C., Masasi, A., Kimaro, G., Ngowi, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60164-7 · Cited by 249
Siedner, M. J., Ng, C. K., Bassett, I. V., Katz, I. T., Bangsberg, D. R., & Tsai, A. C. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu1137 · Cited by 202
The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa
Meyer-Rath, G., Schnippel, K., Long, L., MacLeod, W., Sanne, I., Stevens, W., Pillay, S., Pillay, Y., & Rosen, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036966 · Cited by 158
Self-citationLahuerta, M., Ue, F., Hoffman, S., Elul, B., Kulkarni, S., Wu, Y., Nuwagaba‐Biribonwoha, H., Remien, R. H., El‐Sadr, W., & Nash, D. (2013) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2013.0014 · Cited by 115
Clouse, K., Pettifor, A. E., Maskew, M., Bassett, J., Rie, A. V., Behets, F., Gay, C. L., Sanne, I., & Fox, M. P. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318273ac48 · Cited by 103
Self-citationCohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa
Fox, M. P., Maskew, M., MacPhail, A. P., Long, L. C., Brennan, A. T., Westreich, D. J., MacLeod, W., Majuba, P., & Sanne, I. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys029 · Cited by 96
Self-citationIngle, S. M., May, M., Uebel, K., Timmerman, V., Kotzé, E., Bachmann, M. O., Sterne, J. A. C., Egger, M., & Fairall, L. R. (2010) · AIDS · doi:10.1097/qad.0b013e32833fb71f · Cited by 93
Jani, I. V., Sitoe, N. E., Chongo, P. L., Alfai, E. R., Quevedo, J. I., Tobaiwa, O., Lehe, J. D., & PETER, T. F. (2011) · AIDS · doi:10.1097/qad.0b013e328344f424 · Cited by 92
Siedner, M. J., Lankowski, A. J., Haberer, J. E., Kembabazi, A., Emenyonu, N. I., Tsai, A. C., Muzoora, C. K., Geng, E., Martin, J. N., & Bangsberg, D. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039894 · Cited by 87
Clouse, K., Page‐Shipp, L., Dansey, H., et al. (2012) · South African Medical Journal · doi:10.7196/samj.5851 · Cited by 71
Continuum in HIV care from entry to ART initiation in rural K wa Z ulu‐ N atal, S outh A frica
Plazy, M., Dray‐Spira, R., Orne‐Gliemann, J., Dabis, F., & Newell, M. (2014) · Tropical Medicine & International Health · doi:10.1111/tmi.12301 · Cited by 46
WHO Multicenter Evaluation of FACSCount CD4 and Pima CD4 T-Cell Count Systems
Wade, D., Daneau, G., Aboud, S., Vercauteren, G., Urassa, W. K., & Kestens, L. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000214 · Cited by 38
A meta-analysis of the performance of the PimaTM CD4 for point of care testing
Scott, L. E., Campbell, J., Westerman, L. E., Kestens, L., Vojnov, L., Kohastsu, L., Nkengasong, J. N., PETER, T. F., & Stevens, W. S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0396-2 · Cited by 36
Hoffmann, C. J., Lewis, J. J., Dowdy, D. W., Fielding, K., Grant, A. D., Martinson, N. A., Churchyard, G., & Chaisson, R. E. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182893fb4 · Cited by 34
Mnyani, C. N., McIntyre, J. A., & Myer, L. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318256b651 · Cited by 30
Gous, N. M., Scott, L. E., Potgieter, J., Ntabeni, L., Enslin, S., Newman, R., & Stevens, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085265 · Cited by 26
Black, S., Zulliger, R., Myer, L., Marcus, R., Jeneker, S., Taliep, R., Pienaar, D. C., Wood, R., & Bekker, L. (2013) · South African Medical Journal · doi:10.7196/samj.6565 · Cited by 24
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 396
Benefits and risks of rapid initiation of antiretroviral therapy
Ford, N., Migone, C., Calmy, A., Kerschberger, B., Kanters, S., Nsanzimana, S., Mills, E. J., Meintjes, G., Vitoria, M., Doherty, M., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001671 · Cited by 291
Koenig, S. P., Dorvil, N., Dévieux, J. G., Hedt-Gauthier, B. L., Riviere, C., Faustin, M., Lavoile, K., Perodin, C., Apollon, A., Duverger, L., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002357 · Cited by 287
Labhardt, N. D., Ringera, I., Lejone, T. I., Klimkait, T., Muhairwe, J., Amstutz, A., & Glass, T. R. (2018) · JAMA · doi:10.1001/jama.2018.1818 · Cited by 266
Metadata
- Authors
- Rosen, S., Maskew, M., Fox, M. P., Nyoni, C., Mongwenyana, C., Malete, G., Sanne, I., Bokaba, D., Sauls, C., Rohr, J., & Long, L.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-10
- Volume
- 13
- Issue
- 5
- Pages
- e1002015
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2363480212
- Cited by
- 326
- References
- 20
- FWCI
- 32.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.